# OnCo record nct07815665 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07815665/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07815665", "NCT07815665" ;
  schema:name "A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma"@en ;
  schema:alternateName "HARMONi-GU1"@en ;
  schema:description "A phase 2/3 trial of Ivonescimab, Enfortumab vedotin and Pembrolizumab in bladder & urothelial cancer, run by Summit Therapeutics, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07815665/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07815665> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2/3" ;
  schema:startDate "2026-09-10" ;
  onco:cancers <https://onco.cc/cancers/urothelial/>, <https://onco.cc/cancers/muscle-invasive-bladder-cancer/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/ivonescimab/>, <https://onco.cc/drugs/enfortumab-vedotin/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/summit-therapeutics/> .